NATURE OF STUNNING OF THYROID TISSUE

甲状腺组织致昏的性质

• 批准号: 7376512
• 负责人: JAMES C SISSON
• 金额: $ 0.05万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-04-05 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376512
• 关键词: thyroid neoplasm; tissues

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Stunning, an alteration in the kinetics of therapeutic 131-I induced by the radiation imparted from a prior diagnostic 131-I, is said to occur in residual thyroid tissues of patients with well-differentiated thyroid cancer. This research project will test the hypothesis that, in patients with thyroid cancer, the pattern of loss of 131-I from residual thyroid tissues after low amounts of 131-I (diagnostic) will differ from the pattern of loss after large amounts of 131-I (therapeutic). Ten patients who are to be treated with 131-I for their residual thyroid tissues after surgical thyroidectomies will be recruited. Serial nuclear medicine images of the tissues will be quantified to determine patterns of disappearance of diagnostic 131-I and of subsequent therapeutic 131-I, each over 7 days. An alternative protocol that was more acceptable to potential subjects was introduced: Images of the diagnostic 131-I will be obtained and quantified for only 2 days; this limited period is sufficient for comparing diagnostic and therapeutic 131-I at the time of initial uptake. The patterns should provide evidence either for stunning or, alternatively, for a radiation effect from the larger therapeutic 131-I.

这个子项目是利用由NIH/NCRR资助的中心拨款提供的资源的许多研究子项目之一。子项目和调查员(PI)可能从另一个NIH来源获得了主要资金，因此可能会出现在其他CRISE条目中。列出的机构是针对中心的，而不一定是针对调查员的机构。令人震惊的是，由先前诊断的131-I辐射引起的治疗性131-I动力学的改变，据说发生在分化良好的甲状腺癌患者的残留甲状腺组织中。这项研究项目将检验这样一种假设，即在甲状腺癌患者中，在低剂量131-I(诊断性)后残留甲状腺组织中131-I的丢失模式将不同于大量131-I(治疗性)后的丢失模式。将纳入10名接受131-I治疗的甲状腺切除手术后残留甲状腺组织的患者。组织的连续核医学图像将被量化，以确定诊断性131-I和随后的治疗性131-I的消失模式，每一种都超过7天。介绍了一种更容易被潜在受试者接受的替代方案：仅在2天内获得并量化诊断131-I的图像；这一有限的时间足以比较最初摄取时的诊断和治疗131-I。这些模式应该提供证据，要么证明更大的治疗性131-I的眩晕，要么提供更大的治疗性131-I的辐射效应。